Discussion
A U.S. biotech company has secured $23 million in funding to bring its experimental gel therapy for dystrophic epidermolysis bullosa (DEB) — a topical treatment designed to aid in wound healing — into clinical testing. Boston-based Nova Anchora said the new financing will help advance NvA-021, a gel…